{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T22:18:26Z","timestamp":1649024306899},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.9322-17","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T18:12:32Z","timestamp":1509473552000},"page":"339-342","source":"Crossref","is-referenced-by-count":0,"title":["Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNF\u03b1 Antibody in a Patient with Intestinal Beh\u00e7et Disease"],"prefix":"10.2169","volume":"57","author":[{"given":"Junichi","family":"Iwamoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakuni","family":"Monma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Yara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Krause I, Weinberger A. Behcet&apos;s disease. Curr Opin Rheumatol 20: 82-87, 2008.","DOI":"10.1097\/BOR.0b013e3282f154d1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Saadoun D, Wechsler B. Behcet&apos;s disease. Orphanet J Rare Dis 7: 20, 2012.","DOI":"10.1186\/1750-1172-7-20"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet&apos;s disease. N Engl J Med 341: 1284-1291, 1999.","DOI":"10.1056\/NEJM199910213411707"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 46: e38-e45, 2012.","DOI":"10.1097\/MCG.0b013e3182431d56"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Toda K, Shiratori Y, Yasuda M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behcet&apos;s disease. J Gastroenterol 37: 844-848, 2002.","DOI":"10.1007\/s005350200139"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behcet&apos;s disease. Clin J Gastroenterol 7: 205-212, 2014.","DOI":"10.1007\/s12328-014-0488-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mochizuki M. Immunotherapy for Behcet&apos;s disease. Int Rev Immunol 14: 49-66, 1997.","DOI":"10.3109\/08830189709116844"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Iida M, Kobayashi H, Matsumoto T, et al. Postoperative recurrence in patients with intestinal Behcet&apos;s disease. Dis Colon Rectum 37: 16-21, 1994.","DOI":"10.1007\/BF02047208"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behcet&apos;s disease refractory to conventional medication. Intern Med 52: 1855-1862, 2013.","DOI":"10.2169\/internalmedicine.52.0589"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine 95: e3863, 2016.","DOI":"10.1097\/MD.0000000000003863"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet&apos;s disease. Clin Gastroenterol Hepatol 13: 940-948, e3, 2015.","DOI":"10.1016\/j.cgh.2014.08.042"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hakozaki Y, Mitani K, Okada C, Terada H, Kobari S. Effective treatment of intestinal Behcet&apos;s disease with long-term, low-dose clarithromycin. Case Rep Gastroenterol 7: 122-126, 2013.","DOI":"10.1159\/000350320"},{"key":"13","unstructured":"13. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 15: 527-533, 1989."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrobial Agents Chemotherapy 40: 1366-1370, 1996.","DOI":"10.1128\/AAC.40.6.1366"},{"key":"15","unstructured":"15. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117: 393-405, 2008."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Inoue S, Nakase H, Matsuura M, et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn&apos;s disease. J Gastroenterol Hepatol 22: 984-988, 2007.","DOI":"10.1111\/j.1440-1746.2006.04533.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/3\/57_9322-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T07:48:30Z","timestamp":1570261710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/3\/57_9322-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9322-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}